# Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer

> **NCT02423928** · PHASE1 · COMPLETED · sponsor: **Alden Cancer Therapy II** · enrollment: 18 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** Dendritic cell based cryoimmunotherapy
- **DRUG:** Cyclophosphamide
- **DRUG:** ipilimumab

## Key facts

- **NCT ID:** NCT02423928
- **Lead sponsor:** Alden Cancer Therapy II
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2019-08-16
- **Final completion:** 2019-08-16
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-10-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02423928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02423928, "Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02423928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*